Emulating a randomised trial of unicompartmental and total knee replacement using real world evidence

Edward Burn1, James Weaver2, Daniel Morales3, Albert Prats-Urbí1, Antonella Delmestri2, Victoria Y Strauss1, Ying HE1, Danielle E Robinson1, Rafael Pinedo-Villanueva3, Spyros Kolovos3, Talita Duarte-Salles4, William Spriboviero5, Dahai Yu6, Michel Van Speybroeck7, Ross Williams8, Luis H. John9, Nigel Hughes2, Anthony G. Sena2, Ruth Costello9, Belay Birlie8, David Culliford10, Caroline O’Leary11, Henry Morgan11, Theresa Burkard7, Daniel Prieto-Alhambra1,12, Patrick Ryan2,13

1NDORMS, University of Oxford, UK; 2Janssen Research and Development, Titusville, NJ, USA; 3University of Dundee, UK; 4Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; 5Department of Psychiatry, University of Oxford, UK; 6Reele University, UK; 7Janssen Pharmaceuticals, Beers, Belgium; 8Erasmus University Medical Center, NL; 9Arthritis Research UK Centre for Epidemiology, The University of Manchester, UK; 10OQVA, London, UK; 11University of Basel, Basel, Switzerland; 12University Hospital Basel, Basel, Switzerland; 13GREPMAL Research Group, Idiap Jordi Gol and CIBERfes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain; 14Columbia University, New York, NY, USA

This activity under the European Health Data & Evidence Network (EHDEN) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The sponsor of the study did not have any involvement in the writing of the manuscript or the decision to submit it for publication. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). OPA is funded by a National Institute for Health Research Clinician Scientist award (CS-2013-13-012). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

INTRODUCTION

➢ 264 patients were randomly assigned unicompartmental knee replacement (UKR) and total knee replacement (TKR) in the Total or Partial Knee Arthroplasty Trial (TOPKAT).
➢ We emulated TOPKAT using routinely collected data.

METHODS

➢ Data from 5 observational health care databases covering 2005 to 2018.
➢ Study participants had undergone a UKR or TKR and fulfilled the inclusion criteria for TOPKAT.
➢ Participants were matched based on propensity scores generated using tens of thousands of baseline covariates.
➢ Cox models were fitted to estimate the effect of UKR relative to TKR on post-operative complications (venous thromboembolism, infection, readmission, and mortality), risk of revision, and opioid use.
➢ Hazard ratios were calibrated using control outcomes.

RESULTS

➢ 32,379 and 250,377 individuals who received UKR and TKR were matched and included in the analysis.
➢ UKR was consistently associated with a reduced risk of venous thromboembolism (calibrated hazard ratios (cHRs): 0.47 (0.32 to 0.71) to 0.76 (0.59 to 0.99)), although there was insufficient evidence to conclude there was a reduction in risk of infection, readmission, or mortality.
➢ UKR was also associated with a reduced risk of opioid use (cHRs: 0.72 (0.63 to 0.84) to 0.86 (0.78 to 0.96)), but an increased risk of revision (cHRs: 1.51 (1.24 to 1.88) to 2.16 (1.63 to 3.15)).

Study flow charts, characteristics of study participants before and after matching, propensity score distributions, and results for the primary analysis and each sensitivity analysis are detailed in an interactive web-based application at http://data.ohdsi.org/UkaTkaSafetyEffectiveness

DASHBOARD

Figure 1. Calibrated hazard ratios

DISCUSSION

Key findings
➢ UKR was consistently found to have a decreased risk of post-operative venous thromboembolism relative to TKR, but not of other post-operative complications, such as infection and mortality.
➢ UKR was also consistently found to result in a lower risk of extended opioid use, but a higher risk of revision compared to TKR.

Strengths and limitations
➢ The use of routinely-collected data allowed for a broad assessment of the risks and benefit of UKR and TKR, with the results of this study a useful complement to those from TOPKAT.
➢ Not all of the inclusion criteria for TOPKAT was observable in the data and while patient characteristics were used to generate propensity scores there remains the potential risk of confounding due to unmeasured factors, such as surgeon or surgical centre characteristics.